Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery  
platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents  
selectively into the center of the immune response - i.e., directly into antigen-presenting cells.

RBT currently applies its TargoSphere® technology successfully in various models of infectious  
diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis,  
Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient  
immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and  
autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.

RBT’s enabling technology offers an innovative approach to support the development of novel  
drugs, to render existing drugs more effective, or to provide a path towards extending the  
intellectual property position of already approved treatments.

RBT already partners a growing number of projects with industry and academia. We gladly welcome  
your suggestions for further co-developments and collaborations.
Latest News / Meet RBT
No news

December 4, 2013
Government supports
RBT to develop antibacterial
TargoSphere® formulation

June 11, 2014
RBT on the leap towards
first clinical trials

Recent Press Releases
© Rodos BioTarget GmbH . Medical Park Hannover . Feodor-Lynen-Str. 23 . 30625 Hannover / Germany
September 10, 2014
RBT Provides TargoSphere®
for Therapy Development in Brazil
September 23, 2014
Excellence in Biopharmaceutical Innovation in Germany.